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Background/Aims: The role of Helicobacter pylori eradica-
tion in patients with functional dyspepsia (FD) is still un-
certain. We originally planned a randomized clinical study 
to observe dyspeptic symptoms after H. pylori eradication 
therapy. However, we failed to complete the study; therefore, 
we analyzed the factors that affected the failure of the study. 
Methods: Interviews and questionnaire surveys were con-
ducted to analyze the factors that induced early termination 
from the study. Results: Many patients were screened by 
gastroenterologists at 11 tertiary referral hospitals between 
July 2009 and August 2010; however, only 4 patients met 
the enrollment criteria. Most patients who visited our clinics 
had been experiencing FD symptoms for less than 6 months 
or were already taking medication. They also demanded to 
continue taking medications and using other drugs. Only 3 
of the 4 patients signed informed consent. Conclusions: The 
application of the current Rome III criteria to FD is difficult 
to evaluate in Korean patients with dyspeptic symptoms be-
cause of the early medical evaluation. Most Korean patients 
who were diagnosed with FD by the Rome III criteria did not 
overcome their fear of being unable to use rescue medica-
tions during the study period. (Gut Liver 2011;5:468-471)
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INTRODUCTION
The pathophysiological mechanisms of functional dyspepsia 
(FD) are associated with multifactorial causes such as delayed 
gastric emptying, impaired gastric accommodation to a meal, 
hypersensitivity to gastric distention, altered duodenal sensitiv-
ity to lipids or acid, abnormal duodenojejunal motility, psycho-
social factors, environmental factors, and autonomic dysfunc-
tion.1 Helicobacter pylori status has also been proposed to be 
involved in generating FD symptoms. The Maasricht III consen-
sus report recommended H. pylori eradication for patients with 
H. pylori infection and investigated nonulcer dyspepsia.2 In the 
second Asia-Pacific Consensus Guidelines for H. pylori infec-
tion, H. pylori-infected patients with FD were candidates for 
H. pylori eradication.3 A systemic review showed that H. pylori 
eradication therapy had a small but statistically significant ef-
fect in H. pylori positive nonulcer dyspepsia.4 However, the role 
of H. pylori eradication in patients with FD is still controversial 
because the benefits of H. pylori eradication have not been fully 
evaluated. 
FD has been evaluated again since the Rome III classification 
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was published in 2006.5 FD was redefined as symptoms located 
in the epigastric region, including pain or burning, postprandial 
fullness, or early satiation. No studies have been conducted in 
Korea to evaluate the effect of H. pylori eradication in H. pylori-
infected patients with FD. Therefore, we planned a randomized 
placebo-controlled study to evaluate the clinical usefulness of H. 
pylori eradication therapy in Korean patients with H. pylori in-
fection and FD. However, we failed to enroll sufficient numbers 
of patients for the study. The aim of the present study was to 
evaluate the causes of enrollment failure. 
MATERIALS AND METHODS
1. Overview of original study design
A randomized, double-blind, placebo-controlled study was 
designed for patients who were diagnosed with FD using the 
Rome III criteria. The study protocol was developed by the H. 
pylori and dyspepsia study group of Korean College of Heli-
cobacter and Upper Gastrointestinal Research from November 
2007 to March 2008. The protocol was reviewed by the Medical 
Research Collaborating Center (MRCC) at Seoul National Uni-
versity College of Medicine. It was approved by the Institutional 
Review Boards of 11 medical centers in Korea and the Korean 
Food and Drug Administration (KFDA).
2. Study population 
We enrolled FD patients met the Rome III criteria for FD ac-
cording to inclusion criteria: 1) patients of age 20 to 70 seek-
ing medical care for dyspeptic symptoms; 2) patients who had 
normal endoscopic findings and H. pylori infection (positive 
rapid urease test and/or positive result on histology). We ex-
cluded the following patients: 1) who had reflux symptoms, 
bowel symptoms suggestive of irritable bowel syndrome, he-
matemesis, or any other symptoms and signs indicating serious 
disease; 2) who were treated by histamine-receptor antagonists, 
proton pump inhibitors, prostaglandins, prokinetics, bismuth-
containing compounds, or antibiotics during 4 weeks before the 
study began; 3) who had concomitant diseases that might be 
the causes of dyspeptic symptoms, such as gallstones or pancre-
atic disease, depression or psychosomatic disorders as assessed 
by the Beck Depression Inventory (BDI) and the Somatosensory 
Amplification Scale (SSAS), and the histories of an abdominal 
operation.
3. Planned endoscopy and H. pylori evaluation 
Endoscopy was performed before the screening period, and 
biopsies were taken for the rapid urease test and histology. If a 
patient had a positive rapid urease test or a positive histological 
examination for H. pylori, the patient was considered to have H. 
pylori infection. 
4. Designed study protocol
1) Run-in period
After endoscopy, patients were evaluated for FD using the 
Rome III criteria. Patients diagnosed with FD received diary 
cards and were asked to record eight dyspeptic symptoms and 
their health-related quality of life for a run-in period of 14 
days. The 8 dyspeptic symptoms were selected from among the 
15 symptoms of the Nepean Dyspepsia Index-Korean version 
(NDI-K) and included pain in the upper abdomen, discomfort in 
the upper abdomen, burning in the upper abdomen, inability to 
finish a regular meal, fullness after eating, pressure in the up-
per abdomen, bloating in the upper abdomen, and nausea.6 The 
8 symptoms were estimated by rating frequency (5 subscales), 
intensity (6 subscales), and bothersomeness (5 subscales). 
The NDI-K questionnaire measuring health-related quality of 
life consisted of 25 questions and 5 areas of life including; ten-
sion/sleep (9 items), interference with daily activities (6 items), 
eating/drinking (3 items), knowledge/control (4 items), and 
work/study (3 items).6 For most of the areas, the impact of the 
illness was considered to interfere with a patient’s ability to do 
something or with their enjoyment of that area of life. These 
items were measured using 5-point Likert scales where zero, not 
at all or not applicable; 1, a little; 2, moderately; 3, quite a lot; 
and 4, extremely. The NDI-K quality-of-life score ranges from 0 
to 99, with higher scores indicating a worse quality of life.
2) Treatment period
After the run-in period, patients were randomized, with the 
help of computer-generated randomization codes, to receive 
either H. pylori eradication using triple therapy (30 mg lanso-
prazole twice daily, 500 mg clarithromycin twice daily, and 1 g 
amoxicillin twice daily) for 1 week or a placebo triple therapy 
for 1 week. Compliance with medication was defined as the 
consumption of at least 80% of the medication.
3) Follow-up period
The patients were reevaluated for their symptoms and health-
related quality of life at 4 and 8 weeks after finishing the test 
medication. Diary cards for a given week were collected at that 
week’s visit. At the week 8 visit after finishing the test medica-
tion, the patients underwent a 13C-urea breath test to check H. 
pylori infection status.
4) Assessment of symptoms
Efficacy was assessed at 8 weeks after taking the study medi-
cations using the patient global assessment of efficacy, which 
had 5 grades: symptom-free, markedly improved, moderately 
improved, not changed, and deteriorated. Three secondary effi-
cacy parameters were used in the study. The first parameter was 
a patient’s global assessment of efficacy at 4 weeks. At 8 weeks 
after the medication was completed, improvement in the 8 se-
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lected NDI-K dyspeptic symptoms was considered the second 
parameter, and 4 grades were used to evaluate decreases in the 
total symptom scores: prominent effect (more than 75% reduc-
tion), moderate effect (50% to 75% reduction), mild effect (25% 
to 50% reduction), and no effect (less than 25% reduction). 
This parameter was changed to a disease-specific quality-of-life 
score using the validated NDI-K.6 
5) Statistical analysis
Sample sizes were measured prospectively in the basis of 
intension-to-treat approach. Our calculations were based on 
the results of a previous double-blind placebo-controlled study 
of itopride for FD.7 The placebo response rate of the study was 
41.2% when the patient’s global assessment of efficacy was 
used. To detect a 15% increase in response in the active treat-
ment group, a sample size of 173 per group would give us a 
power of 0.8, a standardized difference (the difference divided 
by the standard deviation) of 0.4, with an alpha significance 
level of 0.05 (two-sided). All variables were examined using the 
chi-square test, Fisher’s exact test, or repeated measures analysis 
of variance. A two-tailed p-value under 0.05 was considered 
statistically significant for all analyses.
5. Surveys for the investigators after closing the study
We prepared a questionnaire for the investigators to evaluate 
the causes of failed patient enrollment. The questionnaire con-
sisted of 4 questions: How many patients did you plan to enroll 
in the study? How many patients did you enroll in the study? 
What were the causes of failed enrollment? What did you think 
about other considerations for successful termination in a future 
study?
RESULTS
Many patients were screened by gastroenterologists at 11 
tertiary referral hospitals from July 2009 to August 2010, but 
only four patients met the criteria for enrollment. The excluded 
patients either had symptoms consistent with irritable bowel 
syndrome or gastroesophageal reflux disease, responded to acid-
suppressive agents, or were already taking H. pylori eradication 
therapy, anti-depressant/anti-anxiety drugs, or prokinetics at 
primary clinics. A significant number of screened patients also 
had short-duration dyspeptic symptoms and wanted to be con-
sidered for an early diagnosis and treatment for their symptoms. 
Only 3 among the 4 patients signed the informed consent. One 
patient, who refused the informed consent, shunned the placebo 
triple-therapy group. They also demanded to have rescue pro-
kinetics or other medications. Two patients finished the study 
according to the study protocol. None of the patients had any 
evidence of depression or psychosomatic disorders as assessed 
by the BDI and the SSAS. However, two is not a sufficient 
sample of patients to satisfy the study goals. This study was 
finally abandoned by the H. pylori and dyspepsia study group 
of Korean College of Helicobacter and Upper Gastrointestinal 
Research in August 2010. We investigated the factors for enroll-
ment failure using a questionnaire survey for researchers. The 
factors that promoted premature closure of this trial were as 
follows. Many patients who had dyspeptic symptoms revealed 
shorter symptom duration than required by the Rome III crite-
ria for FD, so they could not participate. Some avoided joining 
the study due to demands on time or concerns about treatment 
uncertainty. Many patients were already taking medications to 
control dyspeptic symptoms before visiting one of our tertiary 
hospitals.
DISCUSSION
The Rome III criteria were published in 2006,5 and the revi-
sion included changes in the concept of FD. Rome I and Rome II 
defined FD as pain or discomfort located in the upper abdomen 
without a definite structural or biochemical elucidation. How-
ever, no unique single symptom has been found in the vast ma-
jority of patients with FD in subsequent studies. Moreover, most 
symptoms of patients with FD failed to explain physiological 
abnormalities. Under these circumstances, FD was sub-classified 
into epigastric pain syndrome and postprandial distress syn-
drome in the Rome III criteria.8 Many new studies to explore the 
underlying pathophysiological disturbances of the newly classi-
fied FD are expected with introduction of the Rome III criteria. 
Some patients with FD respond to acid-suppressing drugs, 
and the prevalence of nonerosive reflux disease (NERD) with 
FD has not been clarified.9 However, the Rome III criteria have 
a limitation, namely the overlap between NERD and FD.10,11 An 
overlap of NERD with FD is important in a study of H. pylori 
eradication. Therefore, the impact of H. pylori eradication in pa-
tients with FD cannot be precisely evaluated. 
The prevalence of H. pylori is high in Korea.12 We planned 
this study to evaluate the response after H. pylori eradication in 
patients with FD and H. pylori infection. A randomized, double-
blind, placebo-controlled study was designed for patients who 
were diagnosed with FD by the Rome III criteria. The study pro-
tocol was developed by the H. pylori and dyspepsia study group 
of the Korean College of Helicobacter and Upper Gastrointesti-
nal Research from November 2007 to March 2008. The protocol 
was reviewed by MRCC at Seoul National University College of 
Medicine and approved by the KFDA and the Institutional Re-
view Board. The enrollment of patients started in July 2009.
Unfortunately, we failed to enroll enough patients with FD 
and H. pylori infection into our study. We assume that the 
enrollment difficulty depended on several factors. First, the 
diagnosis of FD in the Rome III criteria requires that the on-
set of FD symptoms be longer than 6 months.8 Most patients 
who visited our clinics had symptom durations shorter than 6 
months. A similar situation was reported recently by Manabe 
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et al.13 in Japan. Our Korean dyspeptic patients, like the Japa-
nese patients, had visited the hospital for an evaluation sooner 
than the 6 months defined in the Rome III criteria. We made an 
effort to maintain the Rome III diagnostic criteria for FD dur-
ing the entire study period. Second, many patients were taking 
medicines before visiting our tertiary clinics. We recommended 
to the patients that they interrupt their medications for 2 weeks 
to participate in the study. However, most of them wanted con-
tinuous prescriptions for prokinetics or other agents to control 
their symptoms. This was a critical barrier in this study. Many 
candidates for the study were middle-aged patients who had 
jobs. They also felt burdened by demands on their time imposed 
by participation in this study. 
In conclusion, the current Rome III criteria for FD were dif-
ficult to apply to Korean dyspeptic patients, most of whom had 
symptom durations shorter than 6 months. The majority of pa-
tients who were diagnosed with FD by the Rome III criteria did 
not overcome fears that they could not use rescue medications 
during the study period, even though they did not have depres-
sion or a psychosomatic disorder.
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